SITC 2022 | IL-12 + IL-27 upregulate CD39 expression on CD8+ T-cells + affect CD39+CD8+ T-cell effector function

Saman Maleki, PhD, Western University, London, Canada, discusses an investigation into the expression of CD39, an immunosuppressive molecule, on certain T-cells. Many tumor-associated T-cells express CD39, which is often expressed by exhausted T-cells. An investigation found that IL-12 and IL-27 upregulate CD39 expression on CD8+ T-cells and differentially affect CD39+CD8+ T-cell effector function. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.